[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370416-105":59,"doc-detail-370416-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pan-kras-inhibitors-bi-2493-and-bi-2865-display-potent-antitumor-activity-in-tumors-with-kras-wild-type-allele-amplification","Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification","","KRASG12C-selective inhibitors have highlighted the potential of targeting KRAS in cancer, yet therapies for KRAS wild-type (WT) allele amplification remain limited. This study reports that KRAS WT–amplified tumor models are sensitive to the pan-KRAS small molecules BI-2493 and BI-2865. The inhibitors directly target the “OFF” state of KRAS, producing strong antitumor activity in preclinical settings. Using high-throughput cellular viability profiling across a 900+ cancer cell line panel, the authors identify KRAS WT amplification with copy number >7 as the most responsive subtype. Data indicate an OFF-state inhibitor is better suited than ON inhibition for these tumors.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-kras-inhibitors-bi-2493-and-bi-2865-display-potent-antitumor-activity-in-tumors-with-kras-wild-type-allele-amplification/370416/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-kras-inhibitors-bi-2493-and-bi-2865-display-potent-antitumor-activity-in-tumors-with-kras-wild-type-allele-amplification/370416.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main finding about BI-2493 and BI-2865 in KRAS WT–amplified tumors?","Question",{"text":113,"@type":114},"KRAS wild-type–amplified tumor models show sensitivity to treatment with the pan-KRAS inhibitors BI-2493 and BI-2865, with potent antitumor activity in preclinical models.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do BI-2493 and BI-2865 inhibit KRAS according to the text?",{"text":118,"@type":114},"The inhibitors directly target the “OFF” state of KRAS, resulting in potent antitumor effects in cancers driven by KRASmutant proteins and specifically in KRAS WT–amplified settings described in the study.",{"name":120,"@type":111,"acceptedAnswer":121},"Why does KRAS “OFF” inhibition appear better suited than “ON” inhibition for this tumor subtype?",{"text":122,"@type":114},"The text states that the data suggest a KRAS “OFF” inhibitor is better suited to treat KRAS WT–amplified tumors than a KRAS “ON” inhibitor.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},370416,1790936242,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification  \nAntonio Tedeschi1, Fiorella Schischlik1, Francesca Rocchetti1, Johannes Popow1, Florian Ebner1, Daniel Gerlach1, Antonia Geyer1, Valeria Santoro1, Andrew S. Boghossian2, Matthew G. Rees2, Melissa M. Ronan2, Jennifer A. Roth2, Jesse Lipp1, Matthias Samwer1, Michael Gmachl1, Norbert Kraut1, Mark Pearson1, and Dorothea Rudolph1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | KRASG12C selective inhibitors, such as sotorasib and adagrasib, have raised hopes of targeting other KRAS-mutant alleles in patients with cancer. We report that KRAS wild-type (WT)–amplified tumor models are sensitive to treatment with the small-molecule KRAS inhibitors BI-2493 and BI-2865. These pan-KRAS inhibitors directly target the “OFF” state of KRAS and result in potent antitumor activity in preclinical models of cancers driven by KRASmutant proteins. In this study, we used the high-throughput cellular viability Profiling Relative Inhibition Simultaneously in\u003Cbr>Mixtures assay to assess the antiproliferative activity ofBI-2493 in a 900+ cancer cell line panel, expanding on our previous work. KRAS WT–amplified cancer cell lines, with a copy number >7, were identified as the most sensitive, across cell lines with any KRAS\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | alterations, to our pan-KRAS inhibitors. Importantly, our data suggest that a KRAS “OFF” inhibitor is better suited to treat KRAS WT–amplified tumors than a KRAS “ON” inhibitor. KRAS WT amplification is common in patients with gastroesophageal cancersin which it has been shown to act as a unique cancer driver with little overlap to other actionable mutations. The pan-KRAS inhibitors BI-2493 and BI-2865 show potent antitumor activity in vitro and in vivo in KRAS WT–amplified cell lines from this and other tumor types. In conclusion, this is the first study to demonstrate that direct pharmacologic inhibition of KRAS shows antitumor activity in preclinical models of cancer with KRAS WT amplification, suggesting a novel therapeutic concept for patients with cancers bearing this KRAS alteration. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nActivating KRAS alterations occur in approximately one in seven of all human cancers, making it one of the most prevalent oncogenic drivers (1, 2) . Gain-of-function missense mutations in KRAS are particularly frequent in pancreatic and colorectal cancer and lung adenocarcinoma (2, 3) . Focal, high-level amplification of the KRAS wild-type (WT) allele, an event highly prevalent in gastroesophageal cancer, can additionally result in KRAS activation (4) . Although inhibitors that address the KRASG12Concoprotein have received clinical approval, effective therapies targeting other KRAS alterations, including KRAS WT amplification, remain to be identified.  \nKRAS is a","cbCaifo1UYijJi5g","https://ap.wps.com/l/cbCaifo1UYijJi5g","pdf",9414355,13,"English","# Introduction\n## KRAS alterations and prevalence\n## Targeting KRAS: ON vs OFF state inhibitors\n## KRAS WT allele amplification and therapeutic gap","[{\"question\":\"What is the main finding about BI-2493 and BI-2865 in KRAS WT–amplified tumors?\",\"answer\":\"KRAS wild-type–amplified tumor models show sensitivity to treatment with the pan-KRAS inhibitors BI-2493 and BI-2865, with potent antitumor activity in preclinical models.\"},{\"question\":\"How do BI-2493 and BI-2865 inhibit KRAS according to the text?\",\"answer\":\"The inhibitors directly target the “OFF” state of KRAS, resulting in potent antitumor effects in cancers driven by KRASmutant proteins and specifically in KRAS WT–amplified settings described in the study.\"},{\"question\":\"Why does KRAS “OFF” inhibition appear better suited than “ON” inhibition for this tumor subtype?\",\"answer\":\"The text states that the data suggest a KRAS “OFF” inhibitor is better suited to treat KRAS WT–amplified tumors than a KRAS “ON” inhibitor.\"}]","Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification | PDF",1790188417,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/727256b82ccf158f37a27e089bb95ea7.webp",983,1315,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4162fde925d3b0e7a8f436a884cf4268.webp",982,1314,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1fe01be68a63fff93ff6138c995b19b.webp",981,1312,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/653f02b6586733e28819a04d11548489.webp",980,1311]